There is bad news today for prostate cancer patients. A drug developed by AstraZeneca targeted to late stage cancers patients didn’t not prolong life for those who suffer from prostate cancer. The London based drug company conducted trials with zibotenton which was meant to help prostate cancer patients when other treatments failed. The drug was meant to block the hormone testosterone which can help cancers grow in the prostate. AstraZeneca says they will most likely abandon trials of Study 15 once complete results are determined later this year.
Many drug companies attempt to develop drugs which could help the millions of cancer patients. Prostate cancer, along with mesothelioma and lung cancer have become growing concerns in the health industry and the fight continues to find drugs that can help. For many late stage sufferers, the possibility of a drug that can prolong life is well desired and major drug companies clamor to meet this need but AstraZenaca’s recent failure is disappointing to those men battling prostate cancer.
Cancers that have increasing mortality rates such as prostate cancer, mesothelioma, lung cancer and brain tumors are creating the need for more innovative cures where radiation and chemotherapy fail. The prospect of prolonging the lives of prostate cancer patients and mesothelioma suffers through drug therapy is highly desired and would be profitable for the drug companies. Although Study 15 trials will be suspended it is likely the drug company will continue to study drugs which block the endothelin receptors which increase the growth of cancer cells.
